AVBP vs BMRN · $1.39B cap vs P/E 40, rev $1.76B
ArriVent BioPharma, Inc. Common Stock (AVBP) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
ArriVent BioPharma, Inc. Common Stock (AVBP) is a biotechnology company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
AVBP does not have a complete income-statement cache yet.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
AVBP currently screens at market cap $1.39B. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the AVBP and BMRN stock pages for the full models.
Not investment advice.